1.61 USD
▼-0.22-12.02%
盘后 1.58 -1.86%
2026-09-15
市值
$113.30M
市盈率
—
EPS
-0.65
股息率
—
52 周区间
1.55 – 5.48
成交量
781.02K
Beta
2.77
目标价
7.60
52W 低 1.5552W 高 5.48
价格走势
公司简介
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with...